Displaying 164 (all) recruiting clinical trials.
-
Phase 1/2 Study of PARG Inhibitor ETX-19477 in Patients with Advanced Solid Malignancies
This study is designed to test how the drug moves through the body (pharmacokinetics), how it works (pharmacodynamics), and how well it fights tumors. The ...
-
A RANDOMIZED PHASE 3 TRIAL OF CONTINUOUS VS. INTERMITTENT MAINTENANCE THERAPY WITH ZANUBRUTINIB AS UPFRONT TREATMENT IN OLDER PATIENTS WITH MANTLE CELL LYMPHOMA (INTERCON)
This is a Phase 3 study testing whether continuous or intermittent treatment with the study medicine Zanubrutinib (a kinase inhibitor) and rituximab (a monoclonal antibody ...
-
PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression
This research is for kids and young adults who have a specific kind of brain tumor called DMG (Diffuse Midline Gliomas). We're testing different ...
-
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
This is a phase 2 study testing how well the study medicines vismodegib (a Hedgehog pathway inhibitor), GSK2256098 (a selective focal adhesion kinase (FAK) inhibitor ...
-
A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study has two parts: first, the study team wants to figure out the amount with few side effects of two drugs, nivolumab and ASTX727 ...
-
Open-Label Multicenter Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies
This Phase 1, multi-center, open-label, dose escalation study will enroll and treat approximately 120 adult subjects with relapsed/refractory DLBCL NOS (including DLBCL arising from ... -
PNOC029: Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
This study is designed for patients who have craniopharyngioma (a rare brain tumor). The usual treatment for craniopharyngioma involves surgery and radiation, which helps reduce ...
-
A Phase 3 Randomized Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011)
This is a Phase 3 study testing whether the study medicine sacituzumab tirumotecan ( sac-TMT, antibody-drug conjugate (ADC) targeting TROP2), given alone or with pembrolizumab (immunotherapy ...
-
A Phase 1a/1b Open-Label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study
This is a Phase 1 study testing whether the new medicine BBO-8520 (a KRASG12C on/off inhibitor) is a safe and effective treatment option if ...
-
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkin s Lymphoma
This is a multicenter, open-label Phase 1 study testing a new drug called ARV-393 in adults with advanced non-Hodgkin lymphoma (NHL). The study will look ...